Search results
Results from the WOW.Com Content Network
GlaxoSmithKline (GSK) agreed to pay $1.043 billion relating to false claims arising from off-label promotion. GSK promoted the drugs Paxil and Wellbutrin for unapproved, non-covered uses. GSK also promoted its asthma drug, Advair , for first-line therapy for mild asthma patients even though it was not approved or medically appropriate under ...
GSK also said there remains no consistent or reliable evidence that ranitidine increases cancer risks. The False Claims Act lets whistleblowers sue on behalf of the federal government, and share ...
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
The sale will bring down GSK's current 10.3% holding in the Sensodyne maker, which was spun out and listed on the London Stock Exchange in July 2022. GSK earlier this year sold 240 million shares ...
GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. The company was formed in a merger of GSK and Pfizer's consumer healthcare businesses in 2019. The sale ...
GSK used bribery to stimulate the sales of extravagantly expensive drugs. A GSK rep told Xinhua that her boss said to her, "if the doctor wants money, then give them money; if the doctor wants academic achievements, then provides them with the opportunity." Liang Hong estimated that 30% of the drug prices were used in bribery in GSK China's sales.
GlaxoSmithKline (GSK) closed at $40.22 in the latest trading session, marking a -1.71% move from the prior day.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.